A multidisciplinary approach is crucial for treating recurrent prostate cancer, combining advanced imaging, radiation, and systemic therapies to address microscopic disease. The case report follows Larry Hardesty, who underwent several clinical trials, including PSMA-targeted radioligand therapy, leading to undetectable PSA levels and ...
A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...
Researchers found a major increase in the use of MRI before prostate biopsy, with usage rising from 14% in 2017 to 64% in 2026. This shift is closely tied to the publication of major trials and the adoption of guidelines. The study suggests that MRI use is becoming more widespread, especially among men with prior negative biopsies.
A new study at the University of Oklahoma is testing an interactive app called Connect2Care to increase prostate cancer screening among Black men in Oklahoma. The app provides culturally tailored education, guides users through at-home PSA testing, and connects them with medical professionals.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
A Swedish study published in JAMA Network Open reveals that patients treated with finasteride for benign prostatic hyperplasia experienced fewer serious complications after an acute heart attack. The risk of serious complications was 20.8% among those treated with finasteride, compared to 24.3% among matched controls.
Prostate cancer cells rewire amino acid metabolism to override normal brakes on cholesterol production, fueling hormone therapy resistance. Restricting isoleucine and valine in the diet may slow tumor growth and improve treatment response, while boosting propionyl-CoA levels promotes tumor growth.
A new study found that the majority of veterans with low-risk prostate cancer pursued active surveillance in 2024, up from 27% in 2005. The study followed over 73,000 veterans and showed similar survival outcomes for surveillance compared to treatment.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.
Researchers discovered that engineered nanoparticles directly induce tumor-cell death while transforming the immune microenvironment, supporting further investigation of their therapeutic potential. The particles push cancer cells toward ferroptosis and convert inert immune cells into robust antitumor activity.
A multicenter clinical trial found that adding aglatimagene besadenovec to standard radiation therapy improved disease-free survival for intermediate- and high-risk localized prostate cancer patients. The treatment reduced the risk of recurrence by 27% compared to the placebo group.
Kondapa Naidu Bobba, a nuclear engineering professor, has been awarded the PCF-SNMMI Young Investigator Award to advance prostate cancer research. The award will support his research on radiopharmaceutical therapies to improve treatment outcomes for patients with metastatic castration-resistant prostate cancer.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
Scientists have identified a new cell type and discovered that many normal-looking prostate cells harbor cancer-related changes. The study's findings could lead to new risk factors, earlier detection methods, and more targeted therapies for patients at high risk of aggressive disease.
A study found CREB5 regulates basal and SCL transcriptional programs and tumor-forming phenotypes in prostate cancer, suggesting a central role in aggressive prostate cancer. Disrupting CREB5-regulated pathways may improve therapeutic responses in advanced disease.
UCLA researchers identified a key protein, E2F3, essential for survival in cancer cells lacking the protective gene RB. Blocking E2F3 effectively halted tumor growth, offering a new strategy for treating aggressive cancers.
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Researchers at UH Seidman Cancer Center have developed a reliable tool to predict early biochemical response in metastatic hormone-sensitive prostate cancer patients. This framework enables clinicians to identify high-risk patients at diagnosis, guide early treatment discussions, and potentially improve patient outcomes.
Researchers at Case Western Reserve University have developed a new treatment for advanced prostate cancer that targets the PSMA protein. The treatment, called PSMA-1-DOTA, has been shown to effectively reduce salivary gland damage and eliminate severe side effects associated with current therapies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Researchers have discovered a novel compound that degrades key proteins found in prostate cancer cells, blocking oncogenic androgen receptor signaling. The study found that levels of H2BNTac, p300 and CBP are elevated in prostate cancer compared to normal tissue.
A major international study has identified two enzymes that play a crucial role in helping prostate cancer cells grow and survive. Blocking these enzymes can destabilize the androgen receptor, making tumours more vulnerable to existing therapies.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
A new study found that Black men often view their primary-care providers as gatekeepers for prostate cancer screening, but are frequently dismissed from getting PSA tests. The study's lead author notes that PSA testing can catch the disease earlier and reduce mortality rates by up to 30% if done in the 40s rather than the 50s.
A new study found that a gene expression test can help guide therapy choices for prostate cancer patients with metastatic disease. The Decipher Prostate Genomic Classifier test identified groups of patients who are more likely to benefit from docetaxel chemotherapy, reducing the risk of death by 36%.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models. The findings provide insight into how different classes of FOXA1 mutations operate, shedding light on the complex mechanisms driving prostate cancer progression.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new study by UCLA researchers shows that advanced MRI imaging and targeted focal therapy can help many men with low- to intermediate-risk prostate cancer safely stay on active surveillance long-term, avoiding follow-up biopsies and delaying or avoiding invasive treatments. The findings suggest that routine follow-up biopsy can now be...
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
A new study by Rice University and Vanderbilt University researchers found that combining focused ultrasound with the existing protein therapy TRAIL can significantly reduce tumor size and burden in prostate cancer models. The therapy works by amplifying the anticancer effects of TRAIL via Piezo1 activation, which triggers cell death.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
A new study by UC San Francisco found a marked increase in advanced prostate cancer rates across California since doctors stopped routine screening, with death rates plateauing in most regions. The study emphasizes the need for screening that can identify fatal tumors without raising false alarms.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
Researchers developed an AI model that can identify and measure aggressive prostate cancer lesions with high accuracy. The model's estimates of tumor size were associated with the likelihood of cancer recurrence or metastasis.
Researchers have found that tumors with a short-lived response to hormone therapy had a mutation in the p53 gene, which can be targeted by CDK2 inhibitors. A new study also provides updated dosing guidelines for stereotactic body radiation therapy (SBRT) to minimize complications in patients with spinal metastasis.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.